

MicroRNA-618 Directly Targets Metadherin mRNA to Suppress the Malignant Phenotype of Osteosarcoma Cells by Reducing PTEN-AKT Pathway Output [Retraction]

Li B, Zhao J, Zhao Q, et al. *Onco Targets Ther.* 2019;12:9795–9807.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised over alleged image duplication in Figures 2C, 4C and 5C with similar images from unrelated articles, specifically:

- Figure 2C, panel U2OS miR-NC appears to have been duplicated with a similar image in Figure 2C from Li et al, 2019 (<https://doi.org/10.18632/aging.102280>).
- Figure 2C, panel U2OS miR-618 mimics appears to have been duplicated with a similar image from Figure 5c from Wu et al, 2020 (<https://doi.org/10.1080/15384101.2020.1728024>).
- Figure 4C, panel HOS si-MTDH appears to have been duplicated with a similar image in Figure 4b from Zhao et al, 2020 (<https://doi.org/10.1080/15384101.2020.1749404>).

- Figure 5C, panel HOS miR-618 mimics+pCMV appears to have been duplicated with a similar image in Figure 2C from Li et al, 2019 (<https://doi.org/10.18632/aging.102563>) and Figure 5D from Chen et al, 2019 (<https://doi.org/10.3892/ijmm.2019.4429>).

The authors did not respond to our queries and the Editor determined the findings of the study were no longer valid and advised for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S341751>